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ABSTRACT
Fecal elastase is considered to be a highly sensitive and specific
non-invasive exocrine pancreatic function test. However, en-
teropathy may theoretically cause decreased exocrine pancre-
atic enzyme secretion through alteration of enteric hormone
release.
Objective: The aim of this study was to evaluate the possible
influence of transient small bowel damage on pancreatic elas-
tase secretion.
Methods: We studied 166 children (aged 4 months to 14 years,
mean 2 years); 114 of these children had acute enteritis and 52
children were control subjects (with gastro-intestinal symptoms
or extra-intestinal diseases). Feces were collected from each
patient 3 days after the onset of diarrhea and then tested for
fecal elastase, bacterial pathogens, Rotavirus, and Adenovirus.
Liquid fecal samples were not considered eligible for elastase
measurement. Pancreatic elastase was measured using an
ELISA method (Sche.Bo.Tech, Germany). We classified the
results, expressed in g/g stool, as: severe pancreatic insuffi-
ciency (<100 g/g), moderate pancreatic insufficiency (100 to
200 g/g), and normal (>200 g/g).
Results: In the acute enteritis group we found severe levels in
14 (12%) children, moderate levels in 18 children (16%), and
normal levels in 82 children (72%). In contrast, 52 of 52
(100%) control subjects demonstrated normal results. Statisti-
cal analysis (Wilcoxon rank test) demonstrated a significant
difference between the enteritis and control groups (P < 0.01).
Serial measurement of fecal elastase performed in 10 patients
with enteritis showed a progressive increase of levels in 6 pa-
tients and an early decline with subsequent increases in the
other 4 patients.
Conclusions: Transient exocrine pancreatic insufficiency may
be present in transient small bowel disease, caused by both
bacterial and viral infections, possibly related to reduced en-
teric CCK secretion. JPGN 36:392–396, 2003. Key Words:
Fecal elastase—small bowel—enteritis—pancreatic function
test—CCK. © 2003 Lippincott Williams & Wilkins, Inc.
INTRODUCTION
Fecal elastase (FE) is considered to be a highly sen-
sitive and specific exocrine pancreatic function test. It is
more sensitive than chymotrypsin for severe, moderate,
and mild pancreatic insufficiency (1,2). Pancreatic elas-
tase is not degraded during intestinal transit and thereby
FE reflects exocrine pancreatic function (1,2). Several
reports show its utility in cystic fibrosis with pancreatic
involvement (3–7) and chronic pancreatitis in adults
(8,9). In celiac disease its level seems inversely related to
the degree of enteropathy with restoration of normal
value when healing of mucosal damage occurs (10). In
our study we evaluated the influence of transient small
bowel damage, caused by infection, on FE.
MATERIALS AND METHODS
We sampled 166 patients (range 4 months–14 years, mean
age 2 years) admitted to our hospital; 114 of these patients were
admitted for acute enteritis and there were 52 control subjects
(e.g., respiratory disease, functional abdominal pain, failure to
thrive, and Toddler’s diarrhea). Feces were collected from each
patient at least 48 hours after the onset of diarrhea and tested
for fecal elastase, bacterial pathogens, Rotavirus, and Adeno-
virus. In the last 10 consecutive patients recruited, serial mea-
surements of FE were performed on the 3rd, 7th, 10th, and 15th
day of diarrhea. As dilution of FE (stool water content >85%)
occurs in diarrhea and causes false low results (11,12), liquid
fecal samples were discarded from the study. All stool speci-
mens were frozen at −20°C before analysis. FE was measured
using the ELISA method according to the manufacturer’s in-
structions (ScheBo.Tech, Germany). This measurement in-
volved employing two binding monoclonal antibodies (IC 10A
and II D 5F) to two distinct epitopes of FE. One hundred
milligrams of stool were diluted 1:500 in sample wash buffer
and the FE concentration (g/g wet weight of stools) was mea-
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sured photometrically. The manufacturers provide the follow-
ing clinical ranges: severe pancreatic insufficiency (<100
g/g), moderate pancreatic insufficiency (100200 g/g),
and normal (>200 g/g). We decided to avoid any invasive and
expensive pancreatic diagnostic procedures in our patients be-
cause of the self-limiting nature of the diseases.
For statistical analysis, because none of the data showed a
gaussian distribution, a comparison of paired differences was
performed with the Wilcoxon rank test. Differences with P
values <0.01 were considered significant.
RESULTS
In the acute enteritis group (114 patients) we found
severe FE levels in 14 patients (12%)(5 Rotavirus, 1
Adenovirus, 3 Salmonella, and 5 with non-identified
pathogens), moderate levels in 18 patients (16%)(9 Ro-
tavirus, 3 Salmonella, and 6 with non-identified patho-
gens), and normal levels in 82 patients (72%)(38 Rota-
virus, 3 Adenovirus, 11 Salmonella, and 30 with non-
identified pathogens) (Table 1; Fig. 1). Rotavirus was
found in 52 (46%) patients with enteritis, Adenovirus in
4 patients (3.5%), Salmonella in 17 patients (15%) and
no pathogens were identified in 41 patients (36%). Over-
all, the FE levels were compatible with severe or mod-
erate pancreatic insufficiency in 32 (28%) of patients
with acute enteritis. In contrast, 52 of 52 (100%) control
subjects had normal results. In the 10 patients with in-
fectious diarrhea who received follow-up evaluation, FE
showed two different patterns. In 6 patients (2 Rotavirus,
3 Salmonella, 1 non-identified pathogens), FE showed a
progressive increase with pathologic levels in 3 patients
after 3 days and 2 patients after 7 days, with normaliza-
tion of all patients in 10 days and a further increase by 15
days from the onset of diarrhea (Fig. 2a). In the other 4
patients (3 Rotavirus, 1 non-identified pathogens), we
noticed normal levels at the first determination, but then
decreased levels in the subsequent 2 follow-up samples.
Pathologic FE levels and a concomitant increased num-
ber of stools were seen in 3 patients (2 Rotavirus and 1
non-identified pathogen) at 10 days from onset of diar-
rhea. This was followed by a subsequent increased FE
levels with normalization of FE, by 15 days in 2 patients
(Fig 2b). Neither the diet nor the severity of dehydration
were significantly correlated with the values of FE. Se-
rum amylase tested in patients with enteritis did not cor-
relate with FE.
Statistical analysis showed a significant difference be-
tween the enteritis and control groups (P < 0.01)(Fig. 3).
DISCUSSION
In our study we showed that FE may be severe or
moderately abnormal in 28% of patients with infectious
enteritis. Rotavirus and Salmonella were the most com-
mon identified pathogens (20/32, 62.5%) associated with
pathologic FE levels. As all liquid fecal samples were
discarded and normal results were found in patients with
Toddler’s diarrhea, we considered the possibility of false
positive FE caused by dilution effect very unlikely. Se-
rial measurements of FE showed pathologic levels 3 days
after the onset of diarrhea in 3 children, after 1 week, in
2 of the 3, after 10 days in 3 different patients and after
2 weeks in 2 of the latter 3. Interestingly, the suspected
enteropathy responsible for the decreased pancreatic se-
cretion may take more than 15 days to recover as sup-
ported by pathologic level of follow-up FE determination
in 2 patients with severe infectious enteritis caused by
Rotavirus. Our finding of low FE in 27% of Rotavirus
and 35% of Salmonella enteritis may reflect the presence
of transient enteropathy in these patients. Although we
did not perform biopsies in our patients because of the
self-limiting disorders, our results are consistent with
previous reports of subtotal villous atrophy in either Ro-
tavirus or bacterial enteritis (EPEC, Salmonella) demon-
strated in up to 50% of patients with protracted diarrhea
(13,14).
Preliminary results of our study (15) had suggested the
hypothesis that decreased release of CCK by the dam-
aged intestinal mucosa, even due to a transient infectious
event, could be responsible for low FE results. This
speculation has been recently supported, in 6 patients
with enteropathy and FE pathologic levels, by restoration
of normal pancreatic enzyme levels after secretin-CCK
test (16). These findings provided evidence of the sec-
ondary origin of pancreatic insufficiency in patients with
enteropathy (due to a reduction of pancreatic stimulation
by the inflamed intestine) with normal pancreatic secre-
tory capacity and response to appropriate humoral
stimuli. In the same study, a highly significant correla-
tion between duodenal morphology and inflammation
and levels of FE has been shown in different enteropa-
thies (16).
FE is considered to be an excellent non-invasive
marker of exocrine pancreatic function. The sensitivity
and specificity of FE is greater than 90% for moderate
and severe exocrine pancreatic insufficiency, clearly su-
perior to fecal chymotrypsin (1–3,6,8,9,12,17). It is also
simple, relatively cheap, stable (5), with very low intra-
individual variation (1,2,18). A significant correlation
exists between FE and stimulated duodenal volume, and
the bicarbonate, amylase, lipase, and trypsin concentra-
tion of duodenal aspirates (1,2,6,9). In normal condi-




<100 g/g 100–200 g/g >200 g/g
Rotavirus 52 5 9 38
Salmonella 17 3 3 11
Adenovirus 4 1 / 3
Nonidentified 41 5 6 30
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FIG. 2. (A) Serial measurement of fecal elastase in
6 patients with enteritis. (B) Serial measurement of
fecal elastase in 4 patients with enteritis.
FIG. 1. Fecal elastase levels according to different
enteric pathogens in acute enteritis.
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tions, both neural (entero-pancreatic, cholinergic, vago-
vagal reflexes) and hormonal (cholecystokinin) path-
ways mediate the pancreatic enzyme response to
intestinal stimulants. CCK seems to be the major media-
tor of the response to high loads of amino acids and fatty
acids (19). Immuno-histochemistry identified approxi-
mately 1650 CCK cells per cross-section in the duode-
num of humans (20) and jejunal mucosal integrity is
necessary for the normal secretion of enteric hormones
by the respective cells located in the small bowel mucosa
(10). The close link between the small bowel mucosa and
the exocrine function of the pancreas is highlighted in
celiac disease. In 10 of 30 celiacs (33%) FE was sub-
normal at diagnosis. After 2 months of gluten-free diet,
FE deficiency persisted in only 2 patients, possibly re-
lated to a more severe enteropathy (21), and independent
of nutritional status (22). Recently, FE was found to be
inversely related to the degree of intestinal damage in
celiac disease, emphasizing the role of gluten-related
mucosal damage on abnormal secretion of pancreatic en-
zymes, related possibly to reduced hormonal signaling
(10). In celiacs pancreatic impairment has been associ-
ated with CCK abnormalities (23–25) and is clearly a
reversible phenomenon as it recovers with gluten-free
diet (26,27) and restoration of the mucosa (10).
In recent years, a few patients with different malab-
sorption diseases (celiac disease, Giardiasis, cow-milk
sensitive enteropathy, Crohn disease, and small bowel
syndromes) showed low FE at diagnosis and normaliza-
tion of FE with restoration of small bowel integrity. This
data further supports the close relationship between de-
creased FE and enteropathy regardless of the underlying
diseases (4,16,17,28–30).
In conclusion, low FE and transient exocrine pancre-
atic insufficiency may be present in infectious enteropa-
thy, possibly related to reduced enteric CCK secretion.
As the specificity of FE in differentiation between “pri-
mary” exocrine pancreatic insufficiency and intestinal
malabsorption seems rather poor (30), persisting patho-
logic FE could reflect morphologic and functional de-
rangements of the small bowel mucosa and could indi-
cate further investigation to exclude underlying enter-
opathy. As dilution effect (stool water content >85%)
may account for false positive FE results (11,12), liquid
fecal samples should not be used for FE determination. If
only watery stools are available, lyophilization of the
feces should be performed (11).
REFERENCES
1. Stein J, Jung M, Sziegoleit A, et al. Immunoreactive elastase I:
clinical evaluation of a new noninvasive test of pancreatic func-
tion. Clin Chem 1996;42:222–226.
2. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel,
highly sensitive, and specific tubeless pancreatic function test. Gut
1996;39:580–86.
3. Soldan W, Henker J, Sprossig C. Sensitivity and specificity of
quantitative determination of pancreatic elastase 1 in feces of chil-
dren. J Pediatr Gastroenterol Nutr 1997;24:53–5.
4. Gullo L, Graziano L, Babbini S, et al. Faecal elastase 1 in children
with cystic fibrosis. Eur J Pediatr 1997;156:770–72.
5. Wallis C, Leung T, Cubitt D, et al. Stool elastase as a diagnostic
test for pancreatic function in children with cystic fibrosis. Lancet
1997;350:1001.
6. Walkowiak J, Cichy WK, Herzig K-H. Comparison of fecal
elastase-1 determination with the secretin-cholecystokinin test in
patients with cystic fibrosis. Scand J Gastroenterol 1999;34:
202–07.
7. Cade A, Walters MP, Mc Ginley N, et al. Evaluation of fecal
pancreatic elastase-1 as a measure of pancreatic esocrine function
in children with cystic fibrosis. Pediatr Pulmonol 200;29:172–6.
8. Gullo L, Ventrucci M, Tomassetti P, et al. Fecal elastase 1 deter-
mination in chronic pancreatitis. Dig Dis Sciences 1999;44:210–3.
9. Katschinski M, Schirra J, Bross A, et al. Duodenal secretion and
fecal excretion of pancreatic elastase-1 in healthy humans and
patients with chronic pancreatitis. Pancreas 1997;15:191–200.
10. Nousia-Arvanitakis S, Karagiozoglou-Lamboudes T, Aggouridaki
C, et al. Influence of jejunal morphology changes on exocrine
pancreatic function in celiac disease. J Ped Gastroenterol Nutr
1999;29:81–5.
11. Fisher BP, Hoh S, Wehler, M et al. Fecal elastase 1 in diarrhoea:
FIG. 3. Fecal elastase levels between enteritis and
control group.
LOW FECAL ELASTASE POTENTIALLY RELATED TO TRANSIENT SMALL BOWEL DAMAGE 395
J Pediatr Gastroenterol Nutr, Vol. 36, No. 3, March 2003
lyophilization of stool samples may correct false low results due to
elevated stool water content insufficiency. Digestion 1999;60:
373,A22.
12. Dominguez-Munoz JE, Hieronymus C, Sauerbruck T, et al. Fecal
elastase test: evaluation of a new noninvasive pancreatic function
test. Am J Gastroenterol 1995;90:1834–7
13. Fagundes Neto U, de Castro Ferreira V, Patricio FRS, et al. Pro-
tracted diarrhea: the importance of the enteropathogenic E. coli
(EPEC) strains and Salmonella in its genesis. J Pediatr Gastroen-
terol Nutr 1989;8:207–11.
14. Walker-Smith J, Murch S. Gastroenteritis and its sequelae. In:
Walker-Smith J, Murch S, eds. Diseases of the Small Intestine in
Childhood. Oxford: ISIS Medical Media; Fourth Edition
1999:119–94.
15. Salvatore S, Finazzi S, Melzi d’Eril GV, et al. Low fecal elastase:
could it be also related to small bowel damage? J Ped Gastroen-
terol Nutr 2000;31(S2):S221.
16. Schappi MG, Smith VV, Cubitt D, Milla PJ, Lindley KJ. Faecal
elastase 1 concentration is a marker of duodenal enteropathy. Arch
Dis Child 2002;86:50–3.
17. Walkowiak J. Faecal elastase 1: clinical value in the assessment of
exocrine pancreatic function in children. Eur J Ped 2000;159:
869–70.
18. Phillips IJ, Rowe DJ, Dewar P, et al. Faecal elastase 1: a marker of
exocrine pancreatic insufficiency in cystic fibrosis. Ann Clin Bio-
chem 1999;36:739–42.
19. Singer MV. Pancreatic secretory response to intestinal stimulants:
a review. Scand J Gastroenterol Suppl 1987;139:1–13.
20. Schlegel W, Raptis S, Grube D, et al. Estimation of cholecystokinin-
pancreozymin (CCK) in human plasma and tissue by a specific
radioimmunoassay and the immunohistochemical identification of
pancreozymin-producing cells in the duodenum of humans. Clin
Chim Acta 1977;80:305–16.
21. Carroccio A, Iacono G, Ippolito S, et al. Usefulness of faecal
elastase-1 assay in monitoring pancreatic function in childhood
coeliac disease. Ital J Gastroenterol Hepatol 1998;30:500–4.
22. Carroccio A, Iacono G, Montalto G, et al. Pancreatic insufficiency
in celiac disease is not dependent on nutritional status. Dig Dis Sci
1994;39:2235–41.
23. Hermanz A, Polanco I, Codoceo R, et al. Gastrointestinal peptide
in children with celiac disease. J Pediatr Gastroenterol Nutr 1987;
6:341–5.
24. Polak JM, Bloom SR, McCrossan MV, et al. Cholecystokinin ab-
normalities in celiac disease. Gastroenterology 1978;74:1079–82.
25. Maton PN, Selden AC, Fitzpatrick ML, et al. Defective gallbladder
emptying and cholecystokinin release in coeliac disease: reversal
by gluten-free diet. Gastroenterology 1985;88:191–6.
26. Carroccio A, Iacono G, Montalto G, et al. Exocrine pancreatic
function in children with celiac disease before and after a gluten
free diet. Gut 1991;32:796–9.
27. Collins BJ, Bell PM, Boyd S, et al. Endocrine and exocrine pan-
creatic function in treated celiac disease. Pancreas 1986;1:143–7.
28. Masoero G, Zaffino C, Laudi C, et al. Fecal pancreatic elastase 1
in the work up of patients with chronic diarrhea. Int J Pancreatol
2000;28:175–9.
29. Carroccio A, Verghi F, Santini B, et al. Diagnostic accuracy of
fecal elastase 1 assay in patients with pancreatic maldigestion or
intestinal malabsorption: a collaborative study of the Italian Soci-
ety of Pediatric Gastroenterology and Hepatology. Dig Dis Sci
2001;46:1335–42.
30. Walkowiak J, Herzig KH. Fecal elastase-1 is decreased in villous
atrophy regardless of the underlying disease. Eur J Clin Invest
2001;31:425–30.
Clinical Quiz, continued from page 375
ANSWER: MESENCHYMAL HAMARTOMA
Mesenchymal hamartoma (MH) is a benign liver tumor and accounts for 18% to 29% of these tumors (1). MH
of the liver is usually seen in children in the first 2 years of life. The tumor consists of a solid component and
multiple cysts of various sizes, filled with clear fluid and mucoid material. Without treatment, these lesions can
grow to an enormous size. (In our child the tumor involved the right lobe and the weight was 2.5 Kg (Fig. 2:
histopathologic section)) and may cause severe displacement of the diaphragm. Treatments included marsupi-
alization, simple excision, partial hepatectomy, and orthotopic liver transplantation (2). Recurrence of the tumor
after marsupialization or partial excision could be explained by the hypothesis of Lennington et al. (3). Ac-
cording to this report, recurrence is caused by remnants of the solid part of the tumor or the underlying vascular
anomaly of the hamartoma. Another risk of partial resection may be the development of a malignant tumor; this
occurrence has been reported only twice (4,5). The best treatment of MH of the liver is a complete excision by
enucleation or by partial hepatectomy, because incomplete excision often results in recurrence and operative risk
of enucleation or partial hepatectomy are low. In unresectable cases of MH, a liver transplantation might be
considered as an option. In our patient, a complete excision of the tumor was performed by extended right
hemihepatectomy. The postoperative course was uneventful. Seven years after surgery, the boy is in good health
and ultrasonographic scan showed no recurrence.
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